These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 19525900)
1. Intracerebral interleukin 12 induces glioma rejection in the brain predominantly by CD8+ T cells and independently of interferon-gamma. Vetter M; Hofer MJ; Roth E; Pircher HP; Pagenstecher A J Neuropathol Exp Neurol; 2009 May; 68(5):525-34. PubMed ID: 19525900 [TBL] [Abstract][Full Text] [Related]
2. Immunological responsiveness to interleukin-2-producing brain tumors can be restored by concurrent subcutaneous transplantation of the same tumors. Iwadate Y; Tagawa M; Namba H; Oga M; Kawamura K; Tasaki K; Sakiyama S; Yamaura A Cancer Gene Ther; 2000 Sep; 7(9):1263-9. PubMed ID: 11023199 [TBL] [Abstract][Full Text] [Related]
3. Treatment of intracranial glioma with in situ interferon-gamma and tumor necrosis factor-alpha gene transfer. Ehtesham M; Samoto K; Kabos P; Acosta FL; Gutierrez MA; Black KL; Yu JS Cancer Gene Ther; 2002 Nov; 9(11):925-34. PubMed ID: 12386831 [TBL] [Abstract][Full Text] [Related]
4. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. El Andaloussi A; Sonabend AM; Han Y; Lesniak MS Glia; 2006 Nov; 54(6):526-35. PubMed ID: 16906541 [TBL] [Abstract][Full Text] [Related]
5. Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma. Yuan X; Hu J; Belladonna ML; Black KL; Yu JS Cancer Res; 2006 Mar; 66(5):2630-8. PubMed ID: 16510582 [TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Bracci L; Moschella F; Sestili P; La Sorsa V; Valentini M; Canini I; Baccarini S; Maccari S; Ramoni C; Belardelli F; Proietti E Clin Cancer Res; 2007 Jan; 13(2 Pt 1):644-53. PubMed ID: 17255288 [TBL] [Abstract][Full Text] [Related]
7. Glioma-specific cytotoxic T cells can be effectively induced by subcutaneous vaccination of irradiated wild-type tumor cells without artificial cytokine production. Iwadate Y; Yamaura A; Sakiyama S; Sato Y; Tagawa M Int J Oncol; 2003 Aug; 23(2):483-8. PubMed ID: 12851699 [TBL] [Abstract][Full Text] [Related]
8. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Newcomb EW; Demaria S; Lukyanov Y; Shao Y; Schnee T; Kawashima N; Lan L; Dewyngaert JK; Zagzag D; McBride WH; Formenti SC Clin Cancer Res; 2006 Aug; 12(15):4730-7. PubMed ID: 16899624 [TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. Akasaki Y; Kikuchi T; Homma S; Abe T; Kofe D; Ohno T J Immunother; 2001; 24(2):106-13. PubMed ID: 11265767 [TBL] [Abstract][Full Text] [Related]
10. The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Ehtesham M; Kabos P; Kabosova A; Neuman T; Black KL; Yu JS Cancer Res; 2002 Oct; 62(20):5657-63. PubMed ID: 12384520 [TBL] [Abstract][Full Text] [Related]
11. Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy. Velicu S; Han Y; Ulasov I; Brown IE; El Andaloussi A; Gajewski TF; Lesniak MS J Neuroimmunol; 2006 May; 174(1-2):74-81. PubMed ID: 16504307 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of inducible nitric oxide synthase enhances anti-tumour immune responses in rats immunized with IFN-gamma-secreting glioma cells. Badn W; Hegardt P; Fellert MA; Darabi A; Esbjörnsson M; Smith KE; Janelidze S; Salford LG; Visse E; Siesjö P Scand J Immunol; 2007 Mar; 65(3):289-97. PubMed ID: 17309784 [TBL] [Abstract][Full Text] [Related]
13. In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma. Liu Y; Ehtesham M; Samoto K; Wheeler CJ; Thompson RC; Villarreal LP; Black KL; Yu JS Cancer Gene Ther; 2002 Jan; 9(1):9-15. PubMed ID: 11916248 [TBL] [Abstract][Full Text] [Related]
14. Ocular immune privilege is circumvented by CD4+ T cells, leading to the rejection of intraocular tumors in an IFN-{gamma}-dependent manner. Dace DS; Chen PW; Alizadeh H; Niederkorn JY J Leukoc Biol; 2007 Feb; 81(2):421-9. PubMed ID: 17077163 [TBL] [Abstract][Full Text] [Related]
15. Antitumor treatment using interleukin- 12-secreting marrow stromal cells in an invasive glioma model. Hong X; Miller C; Savant-Bhonsale S; Kalkanis SN Neurosurgery; 2009 Jun; 64(6):1139-46; discussion 1146-7. PubMed ID: 19487894 [TBL] [Abstract][Full Text] [Related]
16. Cure of established GL261 mouse gliomas after combined immunotherapy with GM-CSF and IFNgamma is mediated by both CD8+ and CD4+ T-cells. Smith KE; Fritzell S; Badn W; Eberstål S; Janelidze S; Visse E; Darabi A; Siesjö P Int J Cancer; 2009 Feb; 124(3):630-7. PubMed ID: 18972433 [TBL] [Abstract][Full Text] [Related]
17. Immunogene therapy as a treatment for malignant brain tumors in young mice. Glick RP; Lichtor T; Lin H; Tarlock K; Cohen EP J Neurosurg; 2006 Jul; 105(1 Suppl):65-70. PubMed ID: 16871873 [TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical characterisation of immunological changes at the tumour site after chemo-immunotherapy with doxorubicin, interleukin-2 and interferon-gamma. Lumsden AJ; Codde JP; Van der Meide PH; Gray BN Anticancer Res; 1996; 16(3A):1145-54. PubMed ID: 8702226 [TBL] [Abstract][Full Text] [Related]
19. Eradication of rat malignant gliomas by retroviral-mediated, in vivo delivery of the interleukin 4 gene. Benedetti S; Bruzzone MG; Pollo B; DiMeco F; Magrassi L; Pirola B; Cirenei N; Colombo MP; Finocchiaro G Cancer Res; 1999 Feb; 59(3):645-52. PubMed ID: 9973213 [TBL] [Abstract][Full Text] [Related]
20. Potential usefulness of a cultured glioma cell line induced by Rous sarcoma virus in B10.A mouse as an immunotherapy model. Sakamoto K; Hoshino H; Kiuchi Y; Nakano G; Nagamachi Y Jpn J Exp Med; 1989 Oct; 59(5):173-80. PubMed ID: 2559217 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]